Small-Molecule RNA Therapeutics to Target Prostate Cancer

To understand whether targeting RNA structure using small molecules in the most lethal form of prostate cancer, castration-resistant prostate cancer, the authors used a clinical small molecule, zotatifin, that targeted the RNA helicase and translation factor eukaryotic initiation factor 4A.